Mary‐Ellen Taplin

MedicineComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 26 papers. Top paper: “Transcriptional mediators of treatment resistance in lethal prostate cancer”.

Transcriptional mediators of treatment resistance in lethal prostate cancer

Nature Medicine(2021)10.1038/s41591-021-01244-6

N/A

4.8DataRank · unranked

196 citations

Michael S. Cuoco, Jett Crowdis, Alice Bosma-Moody, Zhenwei Zhang, Kevin Bi +35 more

Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0313

N/A

1.7DataRank · unranked

85 citations

Connie Wu, Peter C. Fridy, Stephanie J. Zhang, Yasmeen Senussi, Justina C. Wolters +54 more

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Nature Communications(2024)10.1038/s41467-023-44514-2

N/A

1.3DataRank · unranked

49 citations

Mary‐Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi +15 more

Transcriptional mediators of treatment resistance in lethal prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.03.19.998450

N/A

1.0DataRank · unranked

26 citations

Michael S. Cuoco, Jett Crowdis, Alice Bosma-Moody, Zhenwei Zhang, Kevin Bi +22 more

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

PLoS ONE(2020)10.1371/journal.pone.0229754

N/A

0.639DataRank · unranked

12 citations

Tuo Deng, Xingbo Long, Xueming Lin, Shulin Wu, Hongbo Wang +6 more

A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5034

N/A

0.461DataRank · unranked

8 citations

Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David J. Einstein +12 more

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.04.20.440657

N/A

0.349DataRank · unranked

7 citations

Alexander T. M. Cheung, Jett Crowdis, Jake R. Conway, Sabrina Y. Camp, Stephanie A. Wankowicz +15 more

Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.05.15.654324

N/A

0.104DataRank · unranked

1 citations

Anwar Abdelnaser, Jeremiah A. Wala, Alexander J Haas, Alfred A. Barney, Eddy Saad +12 more

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

Journal of Clinical Investigation(2022)10.1172/jci161858

N/A

0DataRank · unranked

33 citations

Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh +34 more

Patterns of structural variation define prostate cancer across disease states

JCI Insight(2022)10.1172/jci.insight.161370

N/A

0DataRank · unranked

28 citations

Minjeong Ko, Anna C. H. Hoge, Kelsey Luu, Yuzhen Liu, Magdalena L Russell +13 more

Patterns of Structural Variation Define Prostate Cancer Across Disease States

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.09.475586

N/A

0DataRank · unranked

4 citations

Minjeong Ko, Anna C. H. Hoge, Kelsey Luu, Yuzhen Liu, Magdalena L Russell +13 more

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.11.014

N/A

0DataRank · unranked

18 citations

Fadi Taza, Navonil De Sarkar, Alok K. Tewari, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz +32 more

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad184

N/A

0DataRank · unranked

9 citations

Xiaofei Wang, Evan W. Warner, Andrea Sboner, Matti Annala, Michael Sigouros +13 more

FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)

International Journal of Radiation Oncology*Biology*Physics(2023)10.1016/j.ijrobp.2023.06.401

N/A

0DataRank · unranked

3 citations

Marisa Kollmeier, Dana E. Rathkopf, Richard M. Hoffman, A. Zurita-Saavedra, Daniel E. Spratt +15 more

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.247

N/A

0DataRank · unranked

1 citations

Jamie M. Sperger, Marina N. Sharifi, Yue Shi, Charlotte N. Stahlfeld, Jennifer L. Schehr +9 more

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Cancer Immunology Research(2024)10.1158/2326-6066.cir-22-0306

N/A

0DataRank · unranked

36 citations

Lucia Kwak, Alexander Cheung, Kathryn M. Allaire, Jaqueline Marquez, David D. Yang +21 more

A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer

The Prostate(2024)10.1002/pros.24788

N/A

0DataRank · unranked

2 citations

Alok K. Tewari, D. Gulhan, Ziad Bakouny, Guruprasad Ananda, Hunter Savignano +8 more

Androgen deprivation–mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion

Journal of Clinical Investigation(2025)10.1172/jci192368

N/A

0DataRank · unranked

1 citations

Sen Chen, Luigi Cecchi, Betul Ersoy-Fazlioglu, Joshua W. Russo, Seiji Arai +16 more

Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review

medRxiv(2025)10.1101/2025.04.15.25325837

N/A

0DataRank · unranked

0 citations

Muhammad Umair Anjum, Arifa Bibi, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani, Huan He +19 more

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.111

N/A

0DataRank · unranked

6 citations

Rana R. McKay, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman +14 more

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5597

N/A

0DataRank · unranked

3 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

MP37-02 METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

The Journal of Urology(2020)10.1097/ju.0000000000000886.02

N/A

0DataRank · unranked

0 citations

Tuo Deng, Xueming Lin, Shulin Wu, Zhenwei Zhang, Chin‐Lee Wu +3 more

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps252

N/A

0DataRank · unranked

0 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

UNC Libraries(2020)10.17615/3mgt-tk63

N/A

0DataRank · unranked

0 citations

Derek Raghavan, R. Bryan Rumble, James Williams, James N. Frame, D. Andrew Loblaw +15 more

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer

Cell Reports(2021)10.1016/j.celrep.2021.109665

N/A

0DataRank · unranked

41 citations

Alexander T. M. Cheung, Jett Crowdis, Jake R. Conway, Sabrina Y. Camp, Stephanie A. Wankowicz +15 more

Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5040

N/A

0DataRank · unranked

0 citations

Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova +14 more